AAV.php.b-husod1-sgrna
AAV.php.b-husod1-sgrna has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 1, 2022: “In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model”.
1 paper studies it3 findingsUpdated
See all 1 papers on AAV.php.b-husod1-sgrna
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Biogen
- 3 of 3 findings with company ties
- Animals1
What did studies of AAV.php.b-husod1-sgrna find?
3Studies of AAV.php.b-husod1-sgrna measured 3 outcomes: lifespan, motor function and SOD1.
Lifespan
upin mice1
1 study
Lifespan
upin mice1
AAV.php.b-husod1-sgrna extends lifespan in neonatal H11Cas9 SOD1G93A mice (>110 days).
“extending lifespan by more than 110 days”
Animalsin neonatal H11Cas9 SOD1G93A miceintracerebroventricular injection
Gene therapy
Motor function
upin mice1
1 study
Motor function
upin mice1
AAV.php.b-husod1-sgrna improves motor function in neonatal H11Cas9 SOD1G93A mice.
“restored motor function”
Animalsin neonatal H11Cas9 SOD1G93A miceintracerebroventricular injection
Gene therapy
SOD1
downin mice1
1 study
SOD1
downin mice1
AAV.php.b-husod1-sgrna decreases SOD1 in neonatal H11Cas9 SOD1G93A mice.
“caused robust and sustained mutant huSOD1 protein reduction in the cortex and spinal cord”
Animalsin neonatal H11Cas9 SOD1G93A miceintracerebroventricular injectioncortex and spinal cord
Gene therapy